Askling HH, Nilsson J, Tegnell A, Janzon R, Ekdahl K, 2005. Malaria risk in travelers. Emerg Infect Dis 11 :436–441.
Ranque S, Marchou B, Malvy D, Adehossi E, Laganier R, Tissot-Dupont H, Lotte A, Dydymsky S, Durant J, Stahl JP, Bosseray A, Gaillat J, Sotto A, Cazorla C, Ragneau JM, Brouqui P, Delmont J, Infectio-Sud Group, 2005. Treatment of imported malaria in adults: a multicentre study in France. QJM 98 :737–743.
Bradley DJ, Bannister B, 2003. Health protection Agency Advisory Committee on malaria prevention for UK travellers. Guidelines for malaria prevention in travellers from the United Kingdom for 2003. Commun Dis Public Health 6 :180–199.
Schlagenhauf P, Steffen R, Lobel H, Johnson R, Letz R, Tschopp A, Vranjes N, Bergqvist Y, Ericsson O, Hellgren U, Rombo L, Mannino S, Handschin J, Sturchler D, 1996. Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments: stereochemistry and compliance. Trop Med Int Health 1 :485–494.
Patel SN, Kain KC, 2005. Atovaquone-proguanil for the prophylaxis and treatment of malaria. Expert Rev Anti Infect Ther 3 :849–861.
Mayxay M, Khanthavong M, Lindegardh N, Kiola S, Barends M, Pongvongsa T, Yapon R, Annerberg A, Phompida S, Phetsouvan R, White NJ, Newton PN, 2004. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether- lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People’s Democratic Republic. Clin Infect Dis 39 :1139–1147.
Lefèvre G, Looareesuwan S, Treeprasertsuk S, Krudsood S, Silachamroon U, Gathmann I, Mull R, Bakshi R, 2001. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug–resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 64 :247–256.
Van Vugt M, Ezzet F, Nosten F, Gathmann I, Wilairatana P, Looareesuwan S, White NJ, 1999. No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine. Am J Trop Med Hyg 61 :964–967.
Krudsood S, Chalermrut K, Pengruksa C, Srivilairit S, Silachamroon U, Treeprasertsuk S, Kano S, Brittenham GM, Looareesuwan S, 2003. Comparative clinical trial of two-fixed combinations dihydroartemisinin-napthoquine-trimethoprim (DNP) and artemether-lumefantrine (Coartem/Riamet) in the treatment of acute uncomplicated falciparum malaria in Thailand. Southeast Asian Public Health. 34 :316–321.
Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI, 2005. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 99 :459–467.
Ndayiragije A, Niyungeko D, Karenzo J, Niyungeko E, Barutwanayo M, Ciza A, Bosman A, Moyou-Somo R, Nahimana A, Nyarushatsi JP, Barihuta T, Mizero L, Ndaruhutse J, Delacollette C, Ringwald P, Kamana J, 2004. Efficacy of artemisinin derivative combination therapy for the treatment of uncomplicated falciparum malaria in Burundi; Efficacité de combinaisons thérapeutiques avec des dérivés de lart ’ émisinine dans le traitement de l’accès palustre non-compliqué au Burundi. Trop Med Int Health 9 :673–679.
Martensson A, Stromberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Björkman A, 2005. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 41 :1079–1086.
Mutabingwa TK, Anthony D, Heller A, Hallet R, Ahmed J, Drakely C, Greenwood BM, Whitty CJM, 2005. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodia-quine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 365 :1476–1482.
World Health Organization, 2000. Management of Severe Malaria. A Practical Handbook. Second Edition. Geneva: World Health Organization.
Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, Berman J, 1998. Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 129 :241–244.
Bazett JC, 1920. An analysis of time relation of electrocardiograms. Heart 7 :353–367.
Fridericia LS, 2003. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol 8 :343–351.
Price RN, Simpson JA, Nosten F, Luxemburger C, Hkirjaroen L, ter Kuile F, Chongsuphajaisiddhi T, White N, 2001. Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg 65 :614–622.
Bindschedler M, Lefèvre G, Ezzet F, Schaeffer N, Meyer I, Thomsen M, 2000. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur J Clin Pharmacol 56 :375–381.
Krippner R, Staples J, 2003. Suspected allergy to artemether-lumefantrine treatment of malaria. J Travel Med 10 :303–305.
Vatan R, Pistone T, Millet P, Etienne G, Mercie P, Longy-Boursier M, Malvy D, 2006. Retrospective analysis of 107 imported adult cases of malaria. Experience report of uncomplicated falciparum malaria treatment in adults with oral atovaquone-proguanil. Presse Med. Apr 35 :571–577.
Hitani A, Nakamura T, Ohtomo H, Nawa Y, Kimura M, 2006. Efficacy and safety of atovaquone-proguanil compared with mefloquine in the treatment of nonimmune patients with uncomplicated P. falciparum malaria in Japan. J Infect Chemother 12 :277–282.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 2 | 2 | 2 |
Full Text Views | 321 | 164 | 1 |
PDF Downloads | 140 | 76 | 1 |
The efficacy and safety of artemether-lumefantrine for the treatment of malaria in nonimmune populations are not well defined. In this study, 165 nonimmune patients from Europe and non-malarious areas of Colombia with acute, uncomplicated falciparum malaria or mixed infection including P. falciparum were treated with the six-dose regimen of artemether-lumefantrine. The parasitologic cure rate at 28 days was 96.0% for the per protocol population (119/124 patients). Median times to parasite clearance and fever clearance were 41.5 and 36.8 hours, respectively. No patient had gametocytes after Day 7. Treatment was well tolerated; most adverse events were mild to moderate and seemed to be related to malaria. There were few serious adverse events, none of which were considered to be drug-related. No significant effects on ECG or laboratory parameters were observed. In conclusion, the six-dose regimen of artemether-lumefantrine was effective and well tolerated in the treatment of acute uncomplicated falciparum malaria in nonimmune patients.